ClinicalTrials.gg
CompletedNCT03527147PRISMUpdated Aug 15, 2022

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

A Phase 1 interventional study of AZD9150 and Acalabrutinib in NHL, DLBCL and Non-hodgkin's Lymphoma, sponsored by Acerta Pharma BV. Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2022-08-15.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca — 1 open to participants now, 3 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · AstraZeneca.

Enrollment
9th of 11
30 · median 67
Started
2018
the only one that year
Phase 1
6 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 1, and was the 8th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

1 of the 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).

Read the detailed description

This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's lymphoma (NHL). Each study arm will be conducted in a predefined disease subset. All study arms are open label and allocation to each study arm will not be randomized.

As this master platform protocol has multiple study arms, subjects can be screened for several study arms at once. Likewise, a subject who ends participation in one study arm may be rescreened for participation in another (separate) study arm.

The primary objective of the study is to evaluate the safety of targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL). This protocol has a modular design, with the potential for future treatment arms to be added via protocol amendment.

03

Conditions studied

  • NHL
  • DLBCL
  • Non-hodgkin's Lymphoma
  • Diffuse Large B Cell Lymphoma

Browse trials for

Keywords

  • Acalabrutinib
  • CALQUENCE®
  • ACP-196
  • Platform study
  • Master protocol
  • PRISM
  • Hu-5F9
  • Rituximab
  • ATR
  • STAT3
  • Anti-CD47
  • BRD4
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's enrollment of 30 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.

First submitted after Acerta Pharma BV became part of AstraZeneca.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria For All Arms:

  1. Diagnosis of aggressive Non Hodgkin's Lymphoma (NHL) with histology based on established World Health Organization (WHO) criteria.
  2. Must have received ≥1 for the treatment of current histology, there are no known curative treatment options available, or subject ineligible for potential curative options.
  3. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid . Not applicable for cutaneous lesions.
  4. performance status of ≤2.

Inclusion Criteria for Arm 1:

  1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Inclusion Criteria for Arm 2:

  1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T-cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Inclusion Criteria for Arm 3:

  1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Inclusion Criteria for Arm 4:

  1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Exclusion Criteria:

Exclusion Criteria For All Arms:

  1. History of prior malignancy except for the following: a) Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening and felt to be at low risk for recurrence by treating physician, b) Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanomatous skin cancer, c) Adequately treated carcinoma in situ without current evidence of disease, d) Evidence of severe or uncontrolled systemic disease, or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, history of, or active, bleeding diatheses or uncontrolled active systemic fungal, bacterial, viral, or other infection, or intravenous anti-infective treatment within 2 weeks before first dose of study treatment.
  2. Serologic status reflecting active or C infection.
  3. Prior use of standard antilymphoma therapy or radiation therapy within 14 days of receiving the first dose of study treatment (not including palliative radiotherapy or palliative use).
  4. Requires ongoing therapy, including systemic corticosteroids for treatment of lymphoid cancer or other conditions.
  5. For subjects under DLT review only: Any haematopoietic growth factors or darbepoetin within 14 days of the first dose of study treatment.

Exclusion Criteria for Arm 1:

  1. Presence of central nervous system (CNS) lymphoma or .
  2. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  3. Requires treatment with proton-pump inhibitors.
  4. Requires treatment with strong inhibitors or inducers.

Exclusion Criteria for Arm 2:

  1. Relative hypotension (\< 90/60 mm Hg) or orthostatic hypotension, including a fall in blood pressure of >20 mm Hg.
  2. Uncontrolled hypertension requiring clinical intervention.
  3. At risk for brain perfusion problems based on medical history.
  4. Mean resting (QTc) calculated using Fridericia's formula (QTcF) >470 msec for female subjects and >450 msec for male subjects obtained from 3 (ECGs), or congenital long QT syndrome.
  5. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.
  6. Known to have tested positive for (HIV) \& requires treatment with restricted medications.
  7. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  8. Requires treatment with proton-pump inhibitors.

Exclusion Criteria for Arm 3:

  1. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.
  2. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  3. Requires treatment with proton-pump inhibitors.
  4. Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of RBC transfusions during the 4-week period prior to screening.
  5. History of haemolytic anaemia or Evans syndrome in the last 3 months before enrolment.
  6. Positive IgG component of the direct antiglobulin test (DAT).
  7. Prior treatment with 7 or SIRPα-targeting agents.
  8. to the active substance or to murine proteins, or to any of the other of rituximab

Exclusion Criteria for Arm 4:

  1. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.
  2. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  3. Requires treatment with proton-pump inhibitors.
  4. Requires treatment with CYP3A inhibitors or inducers or substrates of drug transporters.
  5. History of tuberculosis.
  6. Mean resting corrected QT interval (QTcF) >450 msec obtained from 3 electrocardiograms (ECGs); clinically important ECG findings, or risk factors for QTc prolongation.
  7. Subjects receiving antiplatelet or anticoagulant therapies within 28 days of first dose of study drug.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    AZD9150 + Acalabrutinib

    AZD9150 given in combination with acalabrutinib

    Drug: AZD9150 · Drug: Acalabrutinib

  • Experimental
    AZD6738 + Acalabrutinib

    AZD6738 in combination with acalabrutinib

    Drug: Acalabrutinib · Drug: AZD6738

  • Experimental
    Hu5F9-G4 + rituximab + Acalabrutinib

    Hu5F9-G4/rituximab in combination with acalabrutinib

    Drug: Acalabrutinib · Drug: Hu5F9-G4 · Drug: Rituximab

  • Experimental
    AZD5153 + Acalabrutinib

    AZD5153 in combination with acalabrutinib

    Drug: Acalabrutinib · Drug: AZD5153

Interventions

  • AZD9150 will be administered as a 1-hour intravenous (IV) infusion on Days 1, 3, 5 of Cycle 1, followed by weekly infusions (starting Day 8 of Cycle 1 and beyond).

    Also known as: STAT3 inhibitor

  • Acalabrutinib will be administered orally twice daily (bid).

    Also known as: CALQUENCE®, ACP-196

  • AZD6738 will be administered orally twice daily (bid).

    Also known as: ATR inhibitor

  • HU5F9-G4 infusions will be given on Weekly (Day 1, 8, 15, and 22) during the first two 28-day cycles, then will be given every two weeks (Day 1 and Day 15) in Cycle 3 and beyond.

    Also known as: anti-CD47 antibody

  • Rituximab infusions will be given Weekly starting on Day 8 (Day 8, 15, and 22) during the first 28-day cycle (4 weeks), then Day 1 of each 4 week cycle for Cycles 2-6. Starting with Cycle 8, Rituximab will be infused on Day 1 of every other cycle (every 8 weeks).

    Also known as: RITUXAN®

  • AZD5153 will be administered orally once per day (qd).

    Also known as: BRD4 inhibitor

07

What researchers measure

Primary outcomes

  1. Safety of the study treatments when given in combination [Incidence of adverse events]

    Incidence of adverse events

    Time frame: Through to study completion, an average of 1 year

Secondary outcomes

  1. Assessment of the efficacy of each treatment by evaluation of overall response rate using RECIL 2017 response criteria

    The overall response rate (ORR) is defined as the rate of subjects who achieve either a partial response (PR) or complete response (CR) as assessed by investigators before receiving any other anticancer therapy.

    Time frame: Through to study completion, an average of 1 year

  2. Duration of response (DOR) using RECIL 2017 response criteria for the anti-tumour activity of each therapy.

    Duration of Response (DOR) is defined as the time from the first objective response of CR or PR to the time of documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Through to study completion, an average of 1 year

  3. Progression free survival (PFS) using RECIL 2017 response criteria for the anti-tumour activity of each therapy.

    Progression free survival (PFS) is defined as the time from first dose date to documented objective disease progression, or death from any cause, whichever occurs first. Disease progression will be determined by the investigators per standard response criteria as outlined in each respective study arm.

    Time frame: Through to study completion, an average of 1 year

  4. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from first dose until the date of death from any cause.

    Time frame: From the beginning of treatment until the date of death from any cause, assessed up to 12 months

  5. Peak plasma concentration (Cmax) of Study Drug A (Arm 1)

    Time frame: Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only; then predose and approximately 1 hr (end of infusion of Study Drug A) on Day 1 of every odd cycle starting with Cycle 3 through study completion, an average of 1 year

  6. Peak plasma concentration (Cmax) of Study Drug B (Arm 2)

    Time frame: Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1

  7. Area under the plasma concentration versus time curve (AUC) of Study Drug A (Arm 1)

    Time frame: Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only; then predose and approximately 1 hr (end of infusion of Study Drug A) on Day 1 of every odd cycle starting with Cycle 3 through study completion, an average of 1 year

  8. Area under the plasma concentration versus time curve (AUC) of Study Drug B (Arm 2)

    Time frame: Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1

  9. Presence of Anti-Drug Antibody (ADA) titres in subjects treated with Study Drug A

    Time frame: Samples will be collected predose on Days 1 and 8 of Cycle 1 and predose on Day 1 of every odd cycle starting with Cycle 3

  10. Peak plasma concentration (Cmax) of acalabrutinib (Arm 1)

    Time frame: Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only

  11. Area under the plasma concentration versus time curve (AUC) for acalabrutinib (Arm 1)

    Time frame: Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only

  12. Peak plasma concentration (Cmax) of acalabrutinib (Arm 2)

    Time frame: Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1

  13. Area under the plasma concentration versus time curve (AUC) for acalabrutinib (Arm 2)

    Time frame: Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1

08

Study locations

12 sites
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Sarasota, Florida 34232, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    Bethesda, Maryland 20892, United States
  • Research Site
    Omaha, Nebraska 68198, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    London, W1G 6AD, United Kingdom
  • Research Site
    Oxford, OX3 7EJ, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Mar 2021, 33 months.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's 33 months is below that.

Counting every sponsor, half of 195 studies reached it within 53 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2018
First posted
May 17, 2018
StartActual
Jun 19, 2018
Primary completionActual
Mar 31, 2021
CompletionActual
Mar 31, 2021
Last update
Aug 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03527147
Lead sponsor
Acerta Pharma BV
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
May 17, 2018
Start date
Jun 19, 2018
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021
Last update
Aug 15, 2022

Study contacts

Ian Flinn, MD, PhD
study chair · Tennessee Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Danvatirsen · Ceralasertib · Magrolimab · AZD5153

Start the discussion